Free Trial

BioCryst Pharmaceuticals (BCRX) News Today

$6.19
+0.06 (+0.98%)
(As of 05/28/2024 ET)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Aigen Investment Management LP
Aigen Investment Management LP decreased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 91.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 12,670 shares of the biotechnology company's stock after selling 1
Trexquant Investment LP Has $2.53 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Trexquant Investment LP decreased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 28.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 421,516 shares of the biotechnology company's st
GW&K Investment Management LLC Sells 233,180 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
GW&K Investment Management LLC reduced its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 9.1% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,337,683 shares of the biotechnology company's
Nancy J. Hutson Buys 5,000 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Nancy J. Hutson acquired 5,000 shares of the company's stock in a transaction on Monday, May 20th. The shares were bought at an average cost of $6.38 per share, with a total value of $31,900.00. Following the acquisition, the director now directly owns 86,818 shares in the company, valued at $553,898.84. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 4.4% Higher
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 4.4%
BNP Paribas Financial Markets Boosts Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
BNP Paribas Financial Markets increased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 45.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 790,163 shares of the biotechnology company's stock after purchasing an additional 247,195
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. cut its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 26.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 386,885 shares of the biotechnolo
Jump Financial LLC Has $771,000 Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Jump Financial LLC cut its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 68.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 128,771 shares of the biotechnology c
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up on Insider Buying Activity
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up on Insider Buying Activity
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Steven K. Galson Purchases 21,940 Shares
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Steven K. Galson purchased 21,940 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, May 13th. The shares were acquired at an average cost of $5.49 per share, with a total value of $120,450.60. Following the transaction, the director now directly owns 51,551 shares in the company, valued at $283,014.99. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
ORLADEYO® (berotralstat) Approved in Mexico
Equities Analysts Issue Forecasts for BioCryst Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Research analysts at HC Wainwright upped their Q2 2024 earnings per share (EPS) estimates for BioCryst Pharmaceuticals in a research report issued on Tuesday, May 7th. HC Wainwright analyst A. Fein now forecasts that the biotechnology c
FY2028 EPS Estimates for BioCryst Pharmaceuticals, Inc. Decreased by Analyst (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Stock analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for BioCryst Pharmaceuticals in a report issued on Tuesday, May 7th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company wi
BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $15.00 at JMP Securities
JMP Securities boosted their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "market outperform" rating in a report on Tuesday.
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 5.5% Following Better-Than-Expected Earnings
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 5.5% Higher Following Strong Earnings
BioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPS
BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) released its earnings results on Monday. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. The company had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. During the same period in the previous year, the firm posted ($0.28) EPS. The company's revenue for the quarter was up 34.9% on a year-over-year basis.
BioCryst Pharmaceuticals (NASDAQ:BCRX) Receives Buy Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday.
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up to $4.45
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up to $4.45
BioCryst Pharma Shares Jump on Strong 1Q
BioCryst Pharmaceuticals Reports Q1 Loss, Tops Revenue Estimates
BioCryst Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) was the target of unusually large options trading activity on Monday. Traders purchased 2,478 call options on the company. This is an increase of 59% compared to the average daily volume of 1,554 call options.
Get BioCryst Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

Tech GIANT’s Plans to Revolutionize Crypto… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

BCRX Media Mentions By Week

BCRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BCRX
News Sentiment

1.17

0.79

Average
Medical
News Sentiment

BCRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BCRX Articles
This Week

10

4

BCRX Articles
Average Week

Get BioCryst Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:BCRX) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners